Subconjunctival and subscleral fibrosis are the major causes of failure of filtering surgery. Antiproliferative agents have been successfully used to improve the long-term success of this surgery. Recent advancement in the field of glaucoma surgery has been the use of bioengineered, biodegradable, porous collagen-glycosaminoglycan matrix implant in the subconjunctival and/or subscleral space to modify the wound-healing process and reduce scar formation, hence improving the surgical success without the need for anti-fibrotic agents.
Biodegradable, collagen implants have shown favorable results when used with deep sclerectomy. There have been variable results regarding the success of trabeculectomy when combined with these implants. These implants also decrease the dose of mitomycin C required with trabeculectomy and hence, decrease the side effect associated with these drugs.
The use of the biodegradable implants in glaucoma surgery is still evolving and further studies are needed to find the appropriate surgical technique, the ideal size and site of placement and determine their long-term impact on trabeculectomy outcomes and complications.
Cairns JE. Trabeculectomy. Preliminary report of a new method. Am J Ophthalmol 1968 Oct;66(4):831-845.
Watson PG, Barnett F. Effectiveness of trabeculectomy in glaucoma. Am J Ophthalmol 1975 May;79(5):831-845.
Arici MK, Demircan S, Topalkara A, Güler C, Aker H, Arici DS. Effect of conjunctival structure and inflammatory cell counts on intraocular pressure after trabeculectomy. Ophthalmologica 1999;213(6):371-375.
Picht G, Grehn F. Development of the filtering bleb after trabeculectomy. Classification, histopathology, wound healing process. Ophthalmologe 1998 May;95(5):W380-W387.
Beckers HJ, Kinders KC, Webers CA. Five-year results of trabeculectomy with mitomycin C. Graefes Arch Clin Exp Ophthalmol 2003 Feb;241(2):106-110.
WuDunn D, Cantor LB, Palanca-Capistrano AM, Hoop J, Alvi NP, Finley C, Lakhani V, Burnstein A, Knotts SL. A prospective randomized trial comparing intraoperative 5-fluorouracil vs mitomycin C in primary trabeculectomy. Am J Ophthalmol 2002 Oct;134(4):521-528.
Singh K, Mehta K, Shaikh NM, Tsai JC, Moster MR, Budenz DL, Greenfield DS, Chen PP, Cohen JS, Baerveldt GS, et al. Trabeculectomy with intraoperative mitomycin C versus 5-fluorouracil. Prospective randomized clinical trial. Ophthalmology 2000 Dec;107(12):2305-2309.
Yue J, Hu CQ, Lei XM, Qin GH, Zhang Y. Trabeculectomy with amniotic membrane transplantation and combining suture lysis of scleral flap in complicated glaucoma. Zhonghua Yan Ke Za Zhi 2003 Aug;39(8):476-480. (Chin).
Cillino S, Zeppa L, Di Pace F, Casuccio A, Morreale D, Bocchetta F, Lodato G. E-PTFE (Gore-Tex) implant with or without low-dosage mitomycin-C as an adjuvant in penetrating glaucoma surgery: 2 year randomized clinical trial. Acta Ophthalmol 2008 May;86(3):314-321.
Yannas IV, Lee E, Orgill DP, Skrabut EM, Murphy GF. Synthesis and characterization of a model extracellular matrix that induces partial regeneration of adult mammalian skin. Proc Nat Acad Sci USA 1989 Feb;86(3):933-937.
Yannas IV. Studies on the biological activity of the dermal regeneration template. Wound Repair Region 1998 Nov- Dec;6(6):518-524.
Young MJ, Borras T, Walter M, Ritch R. Tissue bioengineering: Potential applications to glaucoma. Arch Ophthalmol 2005 Dec; 123(12):1725-1731.
Yannas IV, Burke JF, Orgill DP, Skrabut EM. Wound tissue can utilize a polymeric template to synthesize a functional extension of skin. Science 1982 Jan;215(4529):174-176.
Hsu WC, Spilker MH, Yannas IV, Rubin PA. Inhibition of conjunctival scarring and contraction by a porous collagenglycosaminoglycan implant. Invest Ophthalmol Vis Sci 2000 Aug;41(9):2404-2411.
Stenzel KH, Miyata T, Rubin AL. Collagen as a biomaterial. Annu Rev Biophys Bioeng 1974;3:231-253.
Chen HS, Ritch R, Krupin T, Hsu WC. Control of filtering bleb structure through tissue bioengineering: an animal model. Invest Ophthalmol Vis Sci 2006 Dec;47(12):5310-5314.
Papaconstantinou D, Georgalas I, Karmiris E, Diagourtas A, Koutsandrea C, Ladas I, Apostolopoulos M, Georgopoulos G. Trabeculectomy with OloGen versus trabeculectomy for the treatment of glaucoma: a pilot study. Acta Ophthalmol 2010 Feb;88(1):80-85.
Cillino S, Di Pace F, Cillino G, Casuccio A. Biodegradable collagen matrix implant versus mitomycin-C as an adjuvant in trabeculectomy: a 24-month, randomized clinical trial. Eye (Lond) 2011 Dec;25(12):1598-606.
Senthil S, Rao HL, Babu JG, Mandal AK, Garudadri CS. Comparison of outcomes of trabeculectomy with mitomycin C vs. ologen implant in primary glaucoma. Indian J Ophthalmol 2013 Jul;61(7):338-342.
Lee SJ, Woo JM, JK Min, CW Kee, JH Yim. The analysis of the clinical findings and effects of biodegradable collagen matrix in trabeculectomy. J Korean Ophthalmol Soc 2012 Feb;53(2):297-305.
Min JK, Kee CW, Sohn SW, Lee HJ, Woo JM, Yim JH. Surgical outcome of mitomycin C-soaked collagen matrix implant in trabeculectomy. J Glaucoma 2013 Aug;22(6):456-462.
Tanuj D, Amit S, Saptorshi M, Meenakshi G. Combined subconjunctival and subscleral ologen implant insertion in trabeculectomy. Eye (Lond) 2013 Jul;27(7):889.
Dada T, Kusumesh R, Bali SJ, Sharma S, Sobti A, Arora V, Panda A. Trabeculectomy with combined use of subconjunctival collagen implant and low-dose mitomycin C. J Glaucoma 2013 Oct-Nov;22(8):659-662.
Narayanaswamy A, Perera SA, Htoon HM, Hoh ST, Seah SK, Wong TT, Aung T. Efficacy and safety of collagen matrix implants in phacotrabeculectomy and comparison with mitomycin C augmented phacotrabeculetcomy at 1 year. Clin Experiment Ophthalmol 2013 Aug;41(6):552-560.
Johnson MS, Sarkisian SR Jr. Using a collagen matrix implant (Ologen) versus mitomycin-C as a wound healing modulator in trabeculectomy with the Ex-PRESS mini glaucoma device: a 12-month retrospective review. J Glaucoma 2014 Dec;23(9): 649-652.
Gupta S, Wadhwani M, Sehgal V, Sharma S, Dada T. Blebitis with scleral abscess in a case of operated trabeculectomy with mitomycin C and a subcunjunctival ologen implant. Eye (Lond) 2014 Mar;28(3):354.
